(RTTNews) - Actinium Pharmaceuticals, Inc. (ATNM), a clinical-stage biopharmaceutical company developing targeted radiotherapies for cancer, said Thursday it has appointed Matt David as chief financial officer.
Mostramos la idea principal publicamente. Crea una cuenta gratis para seguir leyendo el articulo completo, guardarlo, comentarlo y conectarlo con contexto de mercados y OSINT.